1. Academic Validation
  2. Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist

Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist

  • J Med Chem. 2024 Apr 25;67(8):6144-6188. doi: 10.1021/acs.jmedchem.3c01961.
Geoffrey B Varty 1 Clinton E Canal 1 2 Tina A Mueller 1 3 Joshua A Hartsel 1 4 Richa Tyagi 2 Ken Avery 1 Michael E Morgan 1 Amy C Reichelt 1 5 Pradip Pathare 1 Erik Stang 1 Michael G Palfreyman 1 Alex Nivorozhkin 1
Affiliations

Affiliations

  • 1 Cybin IRL Limited, North Wall Quay, 1 Spencer Dock, Dublin 1 DO1 X9R7, Ireland.
  • 2 College of Pharmacy, Department of Pharmaceutical Sciences, Mercer University, 3001 Mercer University Drive, Atlanta, Georgia 30341, United States.
  • 3 BioIVT, Hicksville, New York 11803, United States.
  • 4 Consultant, UPS PO Box #105-650, 25422 Trabuco Road, Lake Forest, California 92630, United States.
  • 5 Faculty of Biomedicine, University of Adelaide, Adelaide, South Australia 5005, Australia.
Abstract

Structure-activity studies of 4-substituted-2,5-dimethoxyphenethylamines led to the discovery of 2,5-dimethoxy-4-thiotrifluoromethylphenethylamines, including CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist. CYB210010 exhibited high agonist potency at 5-HT2A and 5-HT2C receptors, modest selectivity over 5-HT2B, 5-HT1A, 5-HT6, and adrenergic α2A receptors, and lacked activity at monoamine transporters and over 70 other proteins. CYB210010 (0.1-3 mg/kg) elicited a head-twitch response (HTR) and could be administered subchronically at threshold doses without behavioral tolerance. CYB210010 was orally bioavailable in three species, readily and preferentially crossed into the CNS, engaged frontal cortex 5-HT2A receptors, and increased the expression of genes involved in neuroplasticity in the frontal cortex. CYB210010 represents a new tool molecule for investigating the therapeutic potential of 5-HT2 receptor activation. In addition, several other compounds with high 5-HT2A receptor potency, yet with little or no HTR activity, were discovered, providing the groundwork for the development of nonpsychedelic 5-HT2A receptor ligands.

Figures
Products